Single Dose Pharmacokinetics of Efavirenzin Healthy Indian Subjects by Ramachandran, Geetha et al.
SAARC
Journal of Tuberculosis, Lung Diseases and HIV/AIDS
(South Asian Association for Regional Cooperation)
Vol.- IV, No.-1, Year-2007 The Official Journal of the SAARC Tuberculosis & HIV/AIDS Centre
Editorial -------------------------------------------------------------------------------------------------------------v
1. A diagnostic tool to screen for HIV co-infection at the TB DOTS centre in India---------------------1
-Rajasekaran, L. Jeyaseelan,  A. Mahilmaran,  O.R. Krishnarajasekhar,
S. Kumar, S. Annadurai
2. Gender disparity among TB suspects & new TB patients-a record-based retrospective study in 
SAARC Member States ----------------------------------------------------------------------------------------8
-L. Shrestha, K. K. Jha
3. Socio-demographic profile and outcomes of the admitted AIDS patients in BPKIHS, Nepal------19
-Mehta RS, Shrestha R
4. Barriers in seeking health care among TB suspects (TS) an institution-based cross
sectional study in Dhaka, Bangladesh ----------------------------------------------------------------------23
-Jha K K, Begum V,  Islam Md N, Faruq A K M M R, Rahman Md. M, Piryani R M
5. Gender and TB control economic burden on TB patients prior to receiving DOTS in Nepal ------31
-Tara S Bam, Robert S Chapman, Donald A Enarson
6. Single dose pharmacokinetics of Efavirenz in healthy Indian subjects--------------------------------38
-Geetha Ramachandran, A. K. Hemanth Kumar, B. Sukumar, V.Kumaraswami,
 Soumya Swaminathan
7. Blinded rechecking of sputum AFB smears in RNTCP, India: Analysis of Lot Quality
Assurance Sampling data of nine states submitted to National Reference Laboratory
for the year 2006-----------------------------------------------------------------------------------------------44
-Ajay Kumar T, Kumar P, Chauhan L S, Balasangameshwara V H, Shyni S & Shiju S
8. A case of successful prosecution of a defaulter in Anuradhapura district of Sri Lanka--------------51
-Waidyaratne RADKM Deepthini,, Waidyaratne DL
9. Case Report: Changes in immune parameters of a patient with HIV and MDR TB
following chemotherapy and adjunctive immunotherapy-----------------------------------------------54
-N. Thapa, J. L. Stanford
Address:
SAARC Tuberculosis and HIV/AIDS Centre,
Thimi, Bhaktapur,
G.P.O. Box 9517
Tel: 00977-1-6631048, 6632601, 6632477
Fax: 00977-1-6634379
E-mail: saarctb@mos.com.np
Website: www.saarctb.com.np
ISSN 1818 - 9741
Editorial Board from Member Countries
Hayat M. Ahmadzai, Afghanistan
 Md. Abdul Awal Miach, Bangladesh
Gado Tshering, Bhutan
L. S. Chauhan, India
Ibrahim Shaheem, Maldives
Pushpa Malla, Nepal
Hasan Sadiq, Pakistan
Chandra Sarukkali, Sri Lanka
SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS is published and distributed by:
SAARC Tuberculosis and HIV/AIDS Centre
Thimi, Bhaktapur
G.P.O. Box 9517, Kathmandu, Nepal
Tel.: 00977-01-6632601, 6632477, 6631048
Fax: 00977-1-6634379
E-mail: saarctb@mos.com.np
Website: www.saarctb.com.np
SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS
Vol. IV                   No. 1               Year 2007
Editorial Board
The views/statements/opinions etc. expressed in the various articles are those of authors and do not represent
the official views of SAARC Tuberculosis and HIV/AIDS Centre or Editors.
All the scientific materials included in the journal are the copyright of SAARC Tuberculosis and HIV/AIDS
Centre and it is essential to get the written permission prior to reproduction.
Chief Editor
K. K. Jha
Editor
V. S. Salhotra
L.  Shrestha
( i )
Co-editors:
A. Weerakoon
D. K. Khadka
SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS38
SINGLE DOSE PHARMACOKINETICS OF EFAVIRENZ IN
HEALTHY INDIAN SUBJECTS
Geetha Ramachandran, A. K. Hemanth Kumar, B. Sukumar, V.Kumaraswami, Soumya Swaminathan
Tuberculosis Research Centre (Indian Council of Medical Research) Chetput, Chennai, India
Abstract
Background & Objective: Access to antiretroviral therapy in India is improving. Efavirenz (EFV) is a commonly
used non-nucleoside reverse transcriptase inhibitor used to treat HIV infection. No information is available on
the pharmacokinetics of EFV in Indian subjects. The aim of this study was to obtain information on single dose
pharmacokinetics of efavirenz (EFV) in healthy Indian subjects.
Methods: Sixteen adult healthy volunteers (8 males and 8 females) were administered a single oral tablet of 600
mg EFV after an overnight fast. Blood samples were collected at 1, 2, 3, 4, 5, 6, 10, 24 and 48 hours post
dosing. Plasma EFV concentrations were estimated by HPLC, and certain pharmacokinetic variables were
calculated.
Results: Plasma EFV concentrations were higher in females than males at all the time points, the differences
being significant at 1 (p<0.001) and 2 (p=0.05) hours. Females had significantly higher peak concentration (Cmax)
of EFV than males (p=0.05) (3.11 & 1.90 μg/ml).  The inter-individual variability in Cmax and AUC0-48 were 42 and
45% respectively.
Conclusions: This study provides basic information on the pharmacokinetics of EFV in Indian subjects. Females
had higher peak levels of EFV than males. Inter-subject variability was high. Further studies are necessary to
describe the pharmacokinetic profile of EFV under steady state conditions in Indian patients on antiretroviral
treatment.
Key words: Efavirenz, HIV infection, pharmacokinetics, Indian subjects
Correspondence to:
Dr. Soumya Swaminathan
Deputy Director & Head
HIV/AIDS Division
Tuberculosis Research Centre
Mayor V.R. Ramanathan Road
Chetput, Chennai-600 031
Phone: 91-44-28369698
Fax   :  91-44-28362528
E-mail: doctorsoumya@yahoo.com
Introduction
Efavirenz (EFV) is a non-nucleoside reverse
transcriptase inhibitor widely used in the treatment of
HIV infection because of its robust antiviral efficacy
and relatively good pharmacokinetic and safety
profile.1,2 Current recommendations include EFV in
many first-line regimens.2,3 Variability in response to
antiretroviral therapy has been attributed to
differences in virologic, immunologic, pharmacologic,
and behavioral characteristics.4 Significant inter-patient
variability in the kinetics of antiretroviral drugs has
been reported.5,6 Variability in absorption and
disposition of EFV may partially explain the
heterogeneity of response to treatment7. Some
studies have shown a relationship between low and
high EFV plasma levels and treatment failure and CNS
side effects respectively.8 Therefore, elucidation of
the pharmacokinetic profile of EFV and its variability
provides a relevant component of HIV therapeutic
optimization.
SAARC J. TUBERC. LUNG DIS. HIV/AIDS 2007 IV (1) 38 - 43
SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS 39
India has a large number of HIV-positive individuals
and access to antiretroviral therapy is improving. With
increasing number of patients on treatment, it is
important to study the pharmacokinetics of commonly
used antiretroviral drugs. In addition, differences in
EFV pharmacokinetics between various racial / ethnic
groups,9-15 and between males and females11, 15, 16
have been reported.  No information is available on
the pharmacokinetics of EFV in Indian subjects, who
receive treatment with generic drugs, and who could
have genetic differences in the cytochrome P-450
system. We, therefore carried out a study to obtain
basic information on the pharmacokinetics of EFV in
healthy Indian subjects, following administration of a
single dose of 600mg of the drug, which is the
conventional dose used to treat HIV-1 infected
patients. This would give us an idea about the blood
levels of EFV that may be expected in patients who
receive treatment with this drug.
Methods
Participants
Sixteen healthy volunteers aged 18 years and above,
comprising of 8 males and 8 females took part in the
study. All the volunteers were from Tamil Nadu, South
India and belonged to the same ethnic group. They
underwent physical examination by a medical officer.
None of the volunteers was suffering from any illness
or taking concurrent medications at the time of the
study.  The purpose of the study was explained to
the study participants and only those willing to
participate were included. Informed written consent
was obtained from all the study participants before
they took part in the study. Smokers, chronic
alcoholics and females on hormonal birth control pills
were not included in the study.
Drug administration and sample collection
All the volunteers were requested to report to the
clinic division of the Tuberculosis Research Centre,
Chennai, in the morning after an overnight fast. On
the day of the study, about five ml. of blood was
collected (0 hour) in a heparinized container.  A single
tablet of 600 mg EFV (Viranz, Ranbaxy, India) was
administered and blood samples (5 ml.) were
collected at 1, 2, 3, 4, 5, 6, 10, 24 and 48 hours after
drug administration. The total volume of blood
collected from each volunteer during the study period
was about 50 ml. All blood draws were made from
the cephalic vein using an indwelling catheter with
heparin lock. Breakfast and lunch were provided at
two and six hours of drug administration. The blood
samples were centrifuged immediately, plasma
separated and stored at –20oC until assay, which was
carried out within four days.
Assay Procedure
Plasma EFV concentrations were determined by
high performance liquid chromatography (HPLC)
(Shimadzu Corporation, Kyoto, Japan) according to
the method of Langmann et. al,17 using UV detection
set at 246 nm. Efavirenz was extracted into the
organic solvent, and the contents were centrifuged
at 2500rpm for 10 minutes at ambient temperature.
The organic layer was evaporated to dryness, dried
residue reconstituted in the mobile phase and
injected into the HPLC column. Nefazodone was
used as an internal standard. The mobile phase was
a mixture of potassium dihydrogen orthophosphate
and acetonitrile. The retention times of the internal
standard and EFV were 1.8 and 5.8 minutes
respectively.  Unknown concentrations were
derived from linear regression analysis of the peak
height ratios (EFV / internal standard) vs. concentration
curve. The assay was linear from 0.0625 to 10.0μg/
ml with a correlation coefficient value of 0.9992 and
limit of quantification of 0.05μg/ml.  The intra- and
inter-day coefficients of variation were 3.8 and 4.6%
respectively, and recovery of EFV from human
plasma was 98%.
Pharmacokinetic analysis
On each series of plasma EFV concentrations,
certain pharmacokinetic variables were calculated.
Maximum concentrations (C
max
) and the time to attain
Cmax (Tmax) were determined by direct visual
inspection of data.  EFV concentration-time data were
analyzed by a non-compartmental model using
WinNonlin software (Version 5.0.1) (Pharsight
Corporation, Mountain View, CA, USA).  The log
trapezoidal rule was used to compute the exposure
or area under the time concentration curve from 0
to 48 hours (AUC0-48). Elimination rate constant (λ)
was calculated by applying log-linear regression.
This was used to extrapolate AUC to infinity. The
apparent oral clearance (Cl) was calculated as dose/
AUC
0-∞. Half-life (t1/2) was calculated by dividing 0.693
by λ, and volume of distribution (Vd) by dividing Cl
by λ.
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Statistical evaluation
Data were expressed as Median (Range).  The
significance of differences in the pharmacokinetic
parameters between males and females was
evaluated by Mann-Whitney ‘U’ test.  A p value of <
0.05 was considered statistically significant.
Correlation between body weight and that of Cmax and
AUC0-48 & AUC0-∞ were tested using Spearman’s rank
correlation test.
Results
The details of the study participants are given in table
1. Male and female volunteers were similar with
respect to age, body weight and dose of EFV
normalized to body weight. Plasma EFV
concentrations were higher in females than in males
at all the time-points tested (Figure 1), the differences
being significant at 1 (p<0.001) and 2 (p=0.05) hours.
Certain pharmacokinetic variables calculated based
on plasma EFV concentrations in male and female
volunteers are given in Table 2. Females had a
significantly higher C
max
 than males (p=0.05), the
median values being 3.11 and 1.90 μg/ml
respectively. Mean C
max
 values after normalising to
body weight in males and females were 0.036 and
0.055 μg/ml; this difference was also significant
(p=0.05). Although AUC
0-48 & 0-∞and Cl were higher and
lower respectively in females than in males, these
differences were not statistically significant Overall,
the inter-subject variability in C
max
 and AUC
0-48 
was 42
and 45% respectively. There was a negative
correlation between body weight and that of C
max 
and
AUC
0-48 & 0-∞., but these correlations were not
significant.
Table 1 Basic characteristics of study participants
Characteristics Median (Range)
Males (n=8) Females (n=8)
Age (years) 31(25-52) 35(26-47)
Body weight (kg) 65(53-75) 60(48-65)
EFV dose /kg body weight 9.2(8.0-11.3) 10.0(9.2-12.5)
Table 2 Single dose pharmacokinetics of efavirenz (600 mg) in healthy subjects
Pharmacokinetic Variables Median (Range)
Males (n=8) Females (n=8) Overall (n=16)
Peak concentration (μg/ml)* 1.90 (1.41-4.21) 3.11 (1.93-5.15) 2.34 (1.41-5.15)
Time to attain peak concentration (hours) 2.00 (2-4) 2.00 (1-3) 2.00 (1-4)
Exposure 
0-t
 (μg/ml. hours)  35.91(20.66-58.89) 47.62 (27.04-88.76) 39.9 (20.66-88.76)
Exposure 
0-∞ (μg/ml. hours) 64.24 (32.08-100.31) 94.59 (44.72-131.19) 68.36 (32.08-131.19)
Apparent oral clearance (litres/min) 9.53 (5.98-18.7) 6.65 (4.47-13.62) 8.78 (4.47-18.7)
Half-life (hours) 31.77 (23.53-71.71) 41.98 (22.26-74.4) 35.77 (22.26-74.4)
Volume of Distribution(liters) 589.66 (251.56-969.95) 455.09 (167.39-765.46) 525.7 (167.39-969.95)
* denotes p=0.05
Figure 1 Plasma efavirenz concentration in males (n=8) &
females (n=8) at different times points
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Discussion
Presently, there are no data available on EFV
pharmacokinetics in Indian subjects. This study
presents data on certain pharmacokinetic variables
of EFV obtained in healthy volunteers, who were
administered a single dose of 600 mg EFV. Although
considerable data on steady state pharmacokinetics
of EFV are available in other populations, there are
not many reports available on single dose
pharmacokinetics of this drug at a dose of 600 mg.
The SustivaTM product monograph reports a C
max
 of
0.5 to 2.9μg/ml for single oral doses ranging from
100-1600mg in uninfected volunteers18. Since these
values correspond to a wide dose range, a direct
comparison of these values with this study data (Table
2) cannot be made. Howeer, it appears that the
median C
max
 of 2.34μg/ml obtained in this study is on
the higher side than that reported earlier.18 Also a T
max
of 2 hours observed in this study is lower than the
earlier report, which implies that the absorption of
EFV in the Indian subjects was relatively rapid. Single
dose pharmacokinetic data of EFV reported by
Reddy et al19 from nine HIV-infected individuals were
2.7μg/ml, 3.5 hours and 29.97μg/ml.hours (median)
respectively for C
max
, T
max 
and AUC
0-24
. A qualitative
comparison of this data with that of our study shows
that C
max 
values are almost similar, but T
max
 is shorter
in Indian subjects. The AUC values could not be
compared since the time periods were different (24
and 48 hours). However, an AUC
0-48 
value of 39.90
μg/ml.hours obtained in our study appears to be
higher, given the fact that concentrations of EFV
beyond 24 hours were very low. Hence a higher
exposure to EFV, and thereby a lower clearance of
the drug could be expected in Indian patients infected
with HIV. Barrett et al11 have also predicted a lower
clearance of EFV in Asians and Africans relative to
Caucasians.
Recently, several studies have found that sex can
have a modest influence on the pharmacokinetic
profile of certain antiretroviral drugs. Potentially sex-
specific influences, such as endogenous or
exogenous hormones, could impact antiretroviral
tolerance, and influence how women respond and
react to anti-retroviral. A few observational studies
have described a higher frequency of antiretroviral-
related adverse effects among women compared to
men.20,21 Sex-related differences in pharmacokinetics
of EFV have been reported, with females having 20%
higher exposure than males.15, 16 A lower clearance
of EFV in females relative to males has also been
reported.11 Burger et al15 have observed that gender
is an important factor in determining variability in
plasma EFV concentrations, and they have
suggested that one needs to be alert for signs of
EFV-induced toxicity in females. A higher C
max 
(even
after normalizing to body weight)
 
in females than in
males as observed in this study could have
implications for patient management, in terms of
adverse event profiles. The mechanism for sex-
related differences in the pharmacokinetics of EFV,
or antiretroviral drugs in general is not clear. It has
been suggested that this could be due to the fact
that females weigh less and have smaller volumes
compared to males. However, in this study, despite
normalizing C
max 
to body weight, we still observed a
difference between females and males.
Pharmacokinetic differences between patients are an
important factor leading to variability in response to
antiretroviral agents6, 22.  High inter-patient variability
in EFV pharmacokinetics related to CYP-dependent
metabolism and P-glycoprotein-dependent intestinal
secretion,8 and its potential relationship with markers
of efficacy and toxicity have been reported.7, 15 The
high inter-subject variability in C
max
 and AUC observed
in this study point to the fact that monitoring of plasma
concentrations of EFV (therapeutic drug monitoring)
may be useful in certain situations.
Efavirenz undergoes metabolism predominantly
through CYP2B6. Genetic variability of CYP2B6, in
different populations has been reported.12-14 Variation
in CYP2B6 expression among different ethnic groups
has also been reported.12 Race as an important factor
in determining inter-individual variability in plasma EFV
concentrations has been reported15. There are reports
of differences in EFV pharmacokinetics a result of
single nucleotide polymorphisms in the CYP2B6
gene.9-11 A 3-fold higher plasma EFV levels in African-
Americans than European-Americans has been
attributed to a CYP2B6 allelic variant (G516T) that
commonly occurs in the black population.  This single
nucleotide polymorphism was responsible for a lower
rate of clearance of EFV in the African-Americans than
European-Americans, rendering the former group
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more susceptible to CNS side effects.9 A novel
specific CYP2B6 allele (T983C) in Africans has been
shown to cause impaired metabolism of EFV.14
In the absence of EFV pharmacokinetic data in
Indian subjects, this study provides preliminary
information on plasma levels that may be expected
in patients. A limitation of the study was inadequate
sampling time points used to estimate plasma EFV
kinetics. Due to the prolonged half-life of EFV, it
would have been ideal to estimate drug levels up
to 360 hours. However, in this study, due to logistic
reasons, we could not collect blood samples after
48 hours. Generally, pharmacokinetics of drugs
could change in disease states, and it is not easy
to extrapolate the pharmacokinetic parameters from
healthy subjects to patients. Hence pharmacokinetic
studies of EFV in HIV-infected patients on
antiretroviral treatment in India are required. This
would enable us to examine relationships between
EFV pharmacokinetics, efficacy and CNS toxicity.
Further studies are also necessary to determine
whether genetic polymorphisms in drug
metabolizing enzymes, particularly CYP2B6
influence EFV disposition in this population. It would
also be worth exploring sex-related differences in
tolerability and adverse reactions among patients,
as there is some suggestion from our study that
females have higher peak and drug exposure levels
of EFV.
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